Last reviewed · How we verify

NCT05368519

Brijjit® for Wound Closure in Gender Affirming Mastectomies

Withdrawn NA Last updated 9 August 2022
What this trial tests

NA trial testing Brijjit® in Mastectomy. Withdrawn.

Timeline
1 June 2022
Primary endpoint
19 April 2024
19 April 2024

Quick facts

Lead sponsorNYU Langone Health
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Start date1 June 2022
Primary completion19 April 2024
Estimated completion19 April 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 18 to 99, any sex, with Mastectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the use of Brijjit® for wound closure in individuals undergoing bilateral double incision gender affirming mastectomies with a single surgeon (Rachel Bluebond-Langner, MD). The study will be a randomized prospective interventional study utilizing internal controls (one side of chest receives intervention, other serves as control). Primary endpoints will include scar appearance/quality and wound complications

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mastectomy

Currently open trials in the same condition.

Other NYU Langone Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05368519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing